# Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)

Study · id `cardio:ct-nct01371747` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01371747](<https://clinicaltrials.gov/study/NCT01371747>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01371747

Browse, organ or system: Blood vessels; Kidneys; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

## Technical summary

Registry record NCT01371747. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2015-12-17.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 324 participants (enrolled count; ClinicalTrials.gov record NCT01371747, source copy `cardio:ctgov-nct01371747-2021-06-03`, retrieved 2026-10-26)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01371747, source copy `cardio:ctgov-nct01371747-2021-06-03`, retrieved 2026-10-26)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01371747, source copy `cardio:ctgov-nct01371747-2021-06-03`, retrieved 2026-10-26)
- Completion: 2013-06 (actual) (ClinicalTrials.gov record NCT01371747, source copy `cardio:ctgov-nct01371747-2021-06-03`, retrieved 2026-10-26)
- Results first posted: 2015-12-17 (ClinicalTrials.gov record NCT01371747, source copy `cardio:ctgov-nct01371747-2021-06-03`, retrieved 2026-10-26)
- Countries: Croatia; Georgia; Hungary; Serbia; Slovenia (ClinicalTrials.gov record NCT01371747, source copy `cardio:ctgov-nct01371747-2021-06-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01371747-2021-06-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
- Acronym: AMETHYST-DN
- Condition: Chronic Kidney Disease
- Condition: Hypertension
- Condition: Hyperkalemia
- Intervention (Drug): patiromer
- Intervention (Drug): patiromer
- Intervention (Drug): patiromer
- Intervention (Drug): patiromer
- Intervention (Drug): patiromer
- Intervention (Drug): patiromer
- Intervention (Drug): losartan
- Intervention (Drug): spironolactone
- Lead sponsor: Relypsa, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)
- Registry lists this organization as the lead sponsor: Relypsa, Inc. (`cardio:org-relypsa-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN (`cardio:pubmed-29767459`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2612c3b6eaddbff9d891b15f2ae9cb0ab4b42db1f1ffe0ceed4319ad0e201f65
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
